Establishment Labs (NASDAQ:ESTA) Price Target Raised to $95.00

Establishment Labs (NASDAQ:ESTA) had its target price hoisted by Needham & Company LLC from $86.00 to $95.00 in a research report sent to investors on Thursday morning, Marketbeat reports. The firm currently has a buy rating on the stock.

ESTA has been the topic of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Mizuho upped their target price on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Citigroup increased their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. TD Cowen lifted their price target on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, BTIG Research reissued a “buy” rating on shares of Establishment Labs in a research note on Monday, July 13th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $100.25.

Establishment Labs Stock Down 2.1%

Shares of NASDAQ:ESTA opened at $77.42 on Thursday. The firm has a market capitalization of $2.28 billion, a P/E ratio of -59.10 and a beta of 1.07. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96. The stock has a 50 day moving average price of $86.43 and a 200-day moving average price of $74.25. Establishment Labs has a 52-week low of $33.35 and a 52-week high of $97.59.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The firm had revenue of $67.54 million for the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 205.79%. The company’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.57) earnings per share. As a group, equities research analysts anticipate that Establishment Labs will post -1.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Establishment Labs during the 2nd quarter valued at about $135,752,000. Rice Hall James & Associates LLC bought a new stake in shares of Establishment Labs in the second quarter worth approximately $48,134,000. Goldman Sachs Group Inc. raised its holdings in shares of Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after purchasing an additional 438,206 shares during the last quarter. Viking Global Investors LP purchased a new position in shares of Establishment Labs during the second quarter valued at approximately $14,669,000. Finally, Soleus Capital Management L.P. bought a new position in Establishment Labs during the second quarter valued at approximately $9,050,000. 72.91% of the stock is owned by institutional investors.

Key Headlines Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Establishment Labs from $84 to $95 and maintained an Overweight rating, implying substantial upside from the current trading level. Benzinga analyst report
• Positive Sentiment: BTIG increased its price target from $96 to $103 and reiterated a Buy rating, while Needham lifted its target from $86 to $95 and also maintained a Buy rating. These revisions suggest analysts remain optimistic about the company’s growth prospects. The Fly analyst report
• Positive Sentiment: Establishment Labs reported quarterly revenue of $67.54 million, exceeding the $65.79 million analyst estimate and increasing 31.7% year over year. The company also projected 2026 revenue of $269 million to $271 million, above the $267.5 million consensus estimate. Zacks quarterly results report
• Neutral Sentiment: Management indicated that minimally invasive procedures now account for approximately 15% of sales, highlighting potential for longer-term market expansion, but investors may remain focused on the company’s path to profitability. Seeking Alpha revenue outlook report
• Negative Sentiment: The company reported a second-quarter loss of $0.39 per share, wider than the $0.34 expected loss, though the result improved from a $0.57 loss in the year-ago quarter. The earnings miss, continued negative margins, and lack of profitability are likely weighing on the shares. MarketBeat earnings report

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.